Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,335
52-wk High
$7.60
52-wk Low
$1.78

Select another date:

Fri, May 18 2018

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS

BRIEF-RXI Pharmaceuticals Says Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 1.2 Million Shares Of Co's Common Stock

* RXI PHARMACEUTICALS CORP SAYS SELLING STOCKHOLDERS ARE OFFERING ON A RESALE BASIS AN AGGREGATE OF 1.2 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2IbzxKR) Further company coverage:

BRIEF-RXi Pharmaceuticals Announces Grant Of Patent From USPTO For sd-rxRNAs To Treat Fibrotic Disorders

* RXI PHARMACEUTICALS - GRANTED PATENT FROM USPTO FOR METHODS OF USE OF SD-RXRNAS TARGETING CONNECTIVE TISSUE GROWTH FACTOR TO TREAT FIBROTIC DISORDERS Source text for Eikon: Further company coverage:

BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9

* INTRACOASTAL CAPITAL LLC REPORTS 9.2 PERCENT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP, AS OF APRIL 9, 2018 - SEC FILING Source text: [https://bit.ly/2vwj7uq] Further company coverage:

BRIEF-Lincoln Park Capital Reports 9.99 Pct Passive Stake In Rxi Pharmaceuticals

* LINCOLN PARK CAPITAL FUND, LLC REPORTS 9.99 PCT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP AS OF APRIL 9, 2018 SEC FILING Source: (https://bit.ly/2HzQ63m) Further company coverage:

BRIEF-Rxi Pharmaceuticals Announces Closing Of $4.9 Million Registered Direct Offering

* RXI PHARMACEUTICALS ANNOUNCES CLOSING OF $4.9 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market

* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Rxi Pharmaceuticals Files For Mixed Shelf Of Upto $100 Million

* RXI PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING Source text: (https://bit.ly/2If6FB2) Further company coverage:

BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​

* RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​

BRIEF-RXi Pharmaceuticals Qtrly Loss Per Share $0.84

* RXI PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Select another date: